Global Transthyretin Amyloidosis Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Transthyretin Amyloidosis Treatment Market is presumed to reach the market size of nearly USD 14.73 BN by 2030 from USD 6.94 BN in 2022 with a CAGR of 8.72% under the study period 2023 - 2030.

Transthyretin amyloidosis treatment reduces amyloidosis and limits amyloid protein production. Transthyretin amyloidosis is a rare and life-threatening disease. This disease can affect multiple organs of a person with symptoms including loss of appetite, diarrhea, spinal stenosis, constipation, and many more. Transthyretin amyloidosis happens due to various causes like hereditary factors, bone marrow disorder, or even due to some other underlying sickness.

MARKET DYNAMICS:

The presence of supportive reimbursement programs and the growing African-American population drive the transthyretin amyloidosis treatment market. Moreover, the increasing prevalence of disease and rising need for treatment options are anticipated to drive the market's growth soon. Also, the introduction of novel therapies is expected to boost the growth of the transthyretin amyloidosis treatment market. Furthermore, the major factors driving the global transthyretin amyloidosis treatment market are increased awareness, advancements in diagnostic procedures, improvement in healthcare services, rapid economic growth in developing countries, and increased research and development activity. However, low awareness and high cost of transthyretin amyloidosis treatment may hamper the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of transthyretin amyloidosis treatment. The growth and trends of transthyretin amyloidosis treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the transthyretin amyloidosis treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

ATTR-PN
ATTR-CM

By Therapy

Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax)
Supportive Therapy
Pipeline Therapy

By Disease Type

Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type)
Wild Type Amyloidosis

By Distribution Channel

Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Transthyretin Amyloidosis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the transthyretin amyloidosis treatment market include Pfizer Inc., Johnson & Johnson Services Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., BridgeBio Pharma Inc., Bristol-Myers Squibb Company, Acrotech Biopharma, AstraZeneca, Prothena, SOM Biotech. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11219273

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . TRANSTHYRETIN AMYLOIDOSIS TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Therapy
- 3.7.3 Market Attractiveness Analysis By Disease Type
- 3.7.4 Market Attractiveness Analysis By Distribution Channel
- 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY TYPE

6.1 Overview by Type
6.2 Historical and Forecast Data
6.3 Analysis by Type
6.4 ATTR-PN Historic and Forecast Sales by Regions
6.5 ATTR-CM Historic and Forecast Sales by Regions

7 . GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY THERAPY

7.1 Overview by Therapy
7.2 Historical and Forecast Data
7.3 Analysis by Therapy
7.4 Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax) Historic and Forecast Sales by Regions
7.5 Supportive Therapy Historic and Forecast Sales by Regions
7.6 Pipeline Therapy Historic and Forecast Sales by Regions

8 . GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY DISEASE TYPE

8.1 Overview by Disease Type
8.2 Historical and Forecast Data
8.3 Analysis by Disease Type
8.4 Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type) Historic and Forecast Sales by Regions
8.5 Wild Type Amyloidosis Historic and Forecast Sales by Regions

9 . GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

9.1 Overview by Distribution Channel
9.2 Historical and Forecast Data
9.3 Analysis by Distribution Channel
9.4 Hospital Pharmacies Historic and Forecast Sales by Regions
9.5 Specialty Pharmacies Historic and Forecast Sales by Regions
9.6 Retail Pharmacies Historic and Forecast Sales by Regions
9.7 Online Pharmacies Historic and Forecast Sales by Regions

10 . GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1. Overview, Historic and Forecast Sales Analysis
- 10.3.2. North America By Segment Sales Analysis
- 10.3.3. North America By Country Sales Analysis
- 10.3.4. United State Sales Analysis
- 10.3.5. Canada Sales Analysis
- 10.3.6. Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1. Overview, Historic and Forecast Sales Analysis
- 10.4.2. Europe by Segment Sales Analysis
- 10.4.3. Europe by Country Sales Analysis
- 10.4.4. United Kingdom Sales Analysis
- 10.4.5. France Sales Analysis
- 10.4.6. Germany Sales Analysis
- 10.4.7. Italy Sales Analysis
- 10.4.8. Russia Sales Analysis
- 10.4.9. Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1. Overview, Historic and Forecast Sales Analysis
- 10.5.2. Asia Pacific by Segment Sales Analysis
- 10.5.3. Asia Pacific by Country Sales Analysis
- 10.5.4. China Sales Analysis
- 10.5.5. India Sales Analysis
- 10.5.6. Japan Sales Analysis
- 10.5.7. South Korea Sales Analysis
- 10.5.8. Australia Sales Analysis
- 10.5.9. Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1. Overview, Historic and Forecast Sales Analysis
- 10.6.2. Latin America by Segment Sales Analysis
- 10.6.3. Latin America by Country Sales Analysis
- 10.6.4. Brazil Sales Analysis
- 10.6.5. Argentina Sales Analysis
- 10.6.6. Peru Sales Analysis
- 10.6.7. Chile Sales Analysis
- 10.6.8. Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1. Overview, Historic and Forecast Sales Analysis
- 10.7.2. Middle East & Africa by Segment Sales Analysis
- 10.7.3. Middle East & Africa by Country Sales Analysis
- 10.7.4. Saudi Arabia Sales Analysis
- 10.7.5. UAE Sales Analysis
- 10.7.6. Israel Sales Analysis
- 10.7.7. South Africa Sales Analysis
- 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE TRANSTHYRETIN AMYLOIDOSIS TREATMENT COMPANIES

11.1. Transthyretin Amyloidosis Treatment Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12 . COMPANY PROFILES OF TRANSTHYRETIN AMYLOIDOSIS TREATMENT INDUSTRY

12.1. Top Company Share Analysis
12.2. Market Concentration Rate
12.3. Pfizer Inc.
- 12.3.1. Company Overview
- 12.3.2. Company Revenue
- 12.3.3. Products
- 12.3.4. Recent Developments
12.4. Johnson & Johnson Services Inc.
- 12.4.1. Company Overview
- 12.4.2. Company Revenue
- 12.4.3. Products
- 12.4.4. Recent Developments
12.5. Ionis Pharmaceuticals Inc.
- 12.5.1. Company Overview
- 12.5.2. Company Revenue
- 12.5.3. Products
- 12.5.4. Recent Developments
12.6. Alnylam Pharmaceuticals Inc.
- 12.6.1. Company Overview
- 12.6.2. Company Revenue
- 12.6.3. Products
- 12.6.4. Recent Developments
12.7. BridgeBio Pharma Inc.
- 12.7.1. Company Overview
- 12.7.2. Company Revenue
- 12.7.3. Products
- 12.7.4. Recent Developments
12.8. Bristol-Myers Squibb Company
- 12.8.1. Company Overview
- 12.8.2. Company Revenue
- 12.8.3. Products
- 12.8.4. Recent Developments
12.9. Acrotech Biopharma
- 12.9.1. Company Overview
- 12.9.2. Company Revenue
- 12.9.3. Products
- 12.9.4. Recent Developments
12.10. AstraZeneca
- 12.10.1. Company Overview
- 12.10.2. Company Revenue
- 12.10.3. Products
- 12.10.4. Recent Developments
12.11. Prothena
- 12.11.1. Company Overview
- 12.11.2. Company Revenue
- 12.11.3. Products
- 12.11.4. Recent Developments
12.12. SOM Biotech
- 12.12.1. Company Overview
- 12.12.2. Company Revenue
- 12.12.3. Products
- 12.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies